Phase I open-label study of the safety, toleration and pharmacokinetics of CP-609,754, [OSI 754] a farnesyl transferase inhibitor, in subjects with advanced malignant tumors

Trial Profile

Phase I open-label study of the safety, toleration and pharmacokinetics of CP-609,754, [OSI 754] a farnesyl transferase inhibitor, in subjects with advanced malignant tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2005

At a glance

  • Drugs OSI 754 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top